Breaking News, Collaborations & Alliances

Prokarium & Wacker Biotech Sign Manufacturing Contract for Bladder Cancer Immunotherapy

Wacker Biotech will ramp up GMP production of Prokarium’s Salmonella-based immunotherapy.

Author Image

By: Charlie Sternberg

Associate Editor

Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, and Wacker Biotech have signed a contract for the manufacturing of Prokarium’s microbial novel immunotherapy for bladder cancer.   Wacker Biotech will ramp up GMP (Good Manufacturing Practice) production of Prokarium’s Salmonella-based immunotherapy at its biotech site in Amsterdam using its LIBATEC technology.   Preparations for the start of production, technology transfer and scale-up for a Phase 1...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters